Eli Lilly has confirmed that the ACTIV-3 trial of its antibody therapy bamlanivimab (previously known as LY-CoV555) in combination with Gilead’s Veklury (remdesivir) in advanced COVID-19 has been abandoned after it showed no signs of helping patients.
ACTIV-3 was stopped two weeks ago by its sponsors, the National Institute of Allergy and Infectious Diseases (NIAID), part of...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
